主持国家自然科学基金3项，科技部重大新药创制-科技重大专项1项，获得天然药物活性物质与功能国家重点实验室自主课题、教育部留学回国人才启动金以及中国医学科学院药物研究所“引进人才”启动基金的资助。此外作为药理学负责人参与云南省科技厅重大科技专项计划生物医药专项一项。

主要取得了如下科研成果：

1.    靶向长QT综合征的研究：发现心脏钾通道激动剂是治疗长QT综合征行之有效的策略；同时也建立了完整的心脏安全评价体系，包括整套心脏离子通道hERG，Cav1.2, Nav1.5，Kv1.5, Kv4.3 和KCNQ1等通道的细胞水平评价以及体内安全评价；

2.    靶向神经系统疾病相关离子通道的研究 （KCNQ2钾通道、Nav1.7钠通道以及GABA受体），鉴定了多个具有潜在治疗作用的活性化合物和先导化合物；

3.    建立了离子通道和GPCR受体资源丰富的筛选平台体系：包括完备的硬件资源和技术资源。靶点亚型种类众多（涵盖钾通道、钠通道、钙通道、配体门控通道（GABAA受体）以及TRP通道等各个亚型靶点），筛选方法齐全，覆盖多种疾病病种，可开展多种类型的靶点筛选、安全性评价以及相应的药效学评价工作。近年来发表SCI论文20余篇，包括2篇PNAS (IF=9.7），2篇BriJ Pharmacol. (IF=7.773)，1篇PharmacolRes.（IF=5.455），1篇Eur J Med Chem.（IF=5.074）和 1篇 Neuropharmacology (IF=5.018)等。

近年发表论文:

1.     Min Li, HaiboYu *. Identification of WP1066, an inhibitor of JAK2 and STAT3, as a Kv1.3potassium channel blocker.Bri J Pharmacol . 2021, 178(13):2617-2631.

2.     Ning Sheng, Hao Zheng, Min Li, Menglin Li,Zhe Wang, Ying Peng, Haibo Yu*,Jinlan Zhang*. 4,5 caffeoylquinic acid and scutellarin, identified byintegrated metabolomics and proteomics approach as the active ingredients of DengzhanShengmai, act against chronic cerebral hypoperfusion by regulatingglutamatergic and GABAergic synapses. PharmacologicalResearch 152 (2020) 104636. SCI 5.893.

3.      LongjiangHuang*,Jing Ding, Min Li, Zhipeng Hou, Yanru Geng, Xiufen Li and Haibo Yu*.Discoveryof [1,2,4]-triazolo [1,5-a]pyrimidine-7(4H)-one derivatives as positivemodulators of GABAA1 receptor with potent anticonvulsant activity and lowtoxicity. Europe Journal of Medicinal Chemistry. 2020 Jan 1;185:111824.SCI 5.573.

4.     Feng JM, Li M, Zhao JL, Jia XN, Liu JM,Zhang M, Chen RD, Xie KB, Chen DW, Yu HB*,Dai JG*. Three new phenylspirodrimanederivatives with inhibitory effect towards potassium channel Kv1.3 from thefungus Stachybotrys chartarum. JAsian Nat Prod Res. 2019 Sep;21(9):887-894.

5.     Min Li#, Ying Wu#, Beiyan Zou, XiaoliangWang, Min Li and Haibo Yu*. Identification of WB4101, analpha1-adrenoceptor antagonist, as a sodium channel blocker.Mol Pharmacol.2018,  94(2):896-906.(#,co-first authors) （通讯作者）

6.     Wu, Y#., Zou, B#., Liang, L., Li, M., Tao,Y.-X., Yu, H*., Wang, X*., Li, M*., Loperamide inhibits sodium channels to alleviate inflammatoryhyperalgesia, Neuropharmacology.2017, 117: 282-291.  (#,co-first authors) （通讯作者）

7.     YuHB*, Li M, Wang WP, Wang XL*. High throughput screening technologies for ion channels. Acta Pharmacol Sin. 2016,37(1):34-43.（通讯作者）

8.     YuHB*, Zou BY*, Wang XL, Li M. Investigation of miscellaneous hERGinhibition in large diverse compound collection using automated patch-clampassay. Acta Pharmacol Sin. 2016,37(1):111-23.（通讯作者）

9.     Yu,H*., Zou, B., Wang, X., Li, M.. Effect of TyrphostinAG879 on Kv4.2 and Kv4.3 potassium channels. BritJ Pharmacol. 2015, 172(13):3370-82 （通讯作者）

10.  Peters CJ, Yu H, Tien J, Jan YN, Li M, Jan LY*.  Four basic residues critical for the ionselectivity and pore blocker sensitivity of TMEM16A calcium-activated chloridechannels. Proc Natl Acad Sci U S A. 2015 112(11):3547-52.

11.  Du F, Babcock JJ, Yu H, Zou B, Li M*.  Globalanalysis reveals families of chemical motifs enriched for HERG inhibitors. PLoSOne. 2015, 10(2):e0118324.

12.  Yu,H., Lin, Z., Mattmann, M., Zou, B., Terrenoire.C., Zhang, H., Wu, M.,McManus, O. B., Kass, R. S., Lindsley, C. W., *Hopkins, C. R.*, and *Li, M. Dynamic Subunit Stoichiometry Confers a Progressive Continuumof Pharmacological Sensitivity by KCNQ Channels. ProcNatl Acad Sci U S A 110,2013,8732-8737.

13.  Zhou, P., Yu, H., Gu, M., Nan, F., *Gao, Z, and *Li, M. PIP2 alterspharmacological selectivity for epilepsy-causing KCNQ channels. ProcNatl Acad Sci U S A   110,8726-8731, 2013.

14.  Zhang, H.#, Zou, B. #,Yu, H. #, Moretti, A., Wang, X., Yan, W., Babcock,J. J., Bellin, M., McManus, O. B., Tomaselli, G., Nan, F., Laugwitz, K. L., and*Li, M. Modulation of hERG potassium channel gatingnormalizes action potential duration prolonged by dysfunctional KCNQ1 potassiumchannel. Proc Natl Acad Sci U S A 2012,109, 11866-11871.(# 并列第一作者)

15.  Yu,H., Wu, M., Townsend, S. D., Zou, B., Long, S., Daniels, J. S.,McManus, O. B., *Li, M, Lindsley, C. W., and *Hopkins, C. R. Discovery, Synthesis, and Structure Activity Relationship ofa Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization ofML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. ACS chem neurosci 2011, 2, 572-577.

16.  Cheung, Y. Y., Yu, H., Xu, K., Zou, B., Wu, M., McManus, O. B., *Li, M., Lindsley,C. W., and *Hopkins, C. R. Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamidesas novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channelpharmacology: identification of(S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brainpenetrant K(v)7.2 channel inhibitor. J Med Chem 2012, 55, 6975-6979.

17.  Mattmann, M. E., Yu, H., Lin, Z., Xu, K., Huang, X., Long, S., Wu, M., McManus, O.B., Engers, D. W., Le, U. M., *Li, M., Lindsley, C. W., and *Hopkins, C. R.Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide,ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channelactivator. Bioorg Med Chem Lett 2012, 22, 5936-5941.

18.  Du, F., Yu,H., Zou, B., Babcock, J., Long, S., and *Li, M. hERGCentral: a largedatabase to store, retrieve, and analyze compound-human Ether-a-go-go relatedgene channel interactions to facilitate cardiotoxicity assessment in drugdevelopment. Assay Drug Dev Technol 2011, 9, 580-588.

19.  Wang, H. R. #, Wu, M. #,Yu, H., Long, S., Stevens, A.,Engers, D. W., Sackin, H., Daniels, J. S., Dawson, E. S., Hopkins, C. R., *Lindsley, C. W., *Li, M., and McManus, O. B. Selective inhibition of the K(ir)2family of inward rectifier potassium channels by a small molecule probe: thediscovery, SAR, and pharmacological characterization of ML133. ACSChem Biol 2011, 6, 845-856.

20.  Zou, B., Yu, H., Babcock, J. J., Chanda, P., Bader, J. S., McManus, O. B.,and *Li, M. Profiling diverse compounds by flux- and electrophysiology-basedprimary screens for inhibition of human Ether-a-go-go related gene potassiumchannels. Assay Drug Dev Technol 2010, 8, 743-754.

21.  Yu,HB, Li, ZB, Zhang, HX., and Wang, XL. Role ofpotassium channels in Abeta(1-40)-activated apoptotic pathway in culturedcortical neurons. J Neurosci Res 2006, 84,1475-1484.

22.  离子通道作为糖尿病神经性疼痛药物靶点的现状研究。周宇，王晓良，于海波*。药学学报 （ActaPharmaceutica Sinica） 2017,52 (3): 355 −361。

23.  大麻二酚在神经精神疾病中的作用与分子机制研究进展。吴军，于海波*。药学学报 （ActaPharmaceutica Sinica） 2020,55(12): 2800-2810。

24.  神经病理性疼痛的治疗和药物发现现状。宋佳男，刘玉梅*，于海波*。药学学报 （Acta Pharmaceutica Sinica） 2021, 56(3): 679 −688。

25. 癫痫的治疗和药物发现现状。刘颖，孔令飞*，于海波*。药学学报 （Acta Pharmaceutica Sinica） 2021, 56(4): 924 −938。

专著

1.      Yu, H., and Li, M. Highthroughput methods for ion channels. Handbook of Ion Channels. Edited by JieZheng and Matthew C. Trudeau. CRC Press,Pages 199-210. Print ISBN: 978-1-4665-5140-4. 

2.      Yu, H., Lin, Z., Xu, K., Huang,X., Long, S., Wu, M., McManus, O. B., Engers, J. L., Mattmann, M. E., Engers,D. W., Le, U. M., Lindsley, C. W., Hopkins, C. R., and Li, M. Identification ofa novel, small molecule activator of KCNQ1 channels. Probe Reports from the NIH Molecular LibrariesProgram. PMID:    23762928    [PubMed] , 2012.

3.      Yu, H., Wu, M.,Long, S., Hopkins, C. R., Engers, J. L., Townsend, S. D., Lindsley, C. W.,McManus, O. B., and Li, M. A small molecule activator of KCNQ2 and KCNQ4channels. Probe Reports from the NIH Molecular Libraries Program. PMID:    23658954   [PubMed], 2011.

4.      Yu, H., Xu, K., Zou, B., Wu, M., McManus, O. B., Engers, J. L., Cheung, Y.Y., Salovich, J. M., Hopkins, C. R., Lindsley, C. W., and Li, M. Identificationof a novel, small molecule inhibitor of KCNQ2 channels. Probe Reports from the NIH Molecular LibrariesProgram. PMID:    23658963    [PubMed], 2011.

5.      Wu, M., Wang,H., Yu, H., Makhina, E., Xu,J., Dawson, E. S., Hopkins, C. R., Lindsley, C. W., McManus, O. B., and Li, M.A potent and selective small molecule Kir2.1 inhibitor. Probe Reports from the NIH Molecular LibrariesProgram. PMID: 21433384 [PubMed], 2010.